Qu Biologics and TransBIOTech Awarded $450K Applied Research and Development Grant Funding
11 mars 2024 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Qu Biologics Receives Accelerating Clinical Trial (ACT) Funding for PERIOP-06 Clinical Trial
14 nov. 2023 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics
23 janv. 2023 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform
14 déc. 2022 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Qu Biologics to Receive Additional Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly
17 oct. 2022 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer
26 sept. 2022 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy...
Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead
20 juil. 2022 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, July 20, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...
Qu Biologics Closes USD$12M Equity Financing
21 mars 2022 08h00 HE
|
Qu Biologics, Inc.
BURNABY, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...
Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress
13 juil. 2021 08h00 HE
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biotechnology company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Qu Biologics Receives Additional Funding to Accelerate Clinical Development of Qu’s First-in-Class Immunotherapeutic for COVID-19 Prevention and Treatment
23 juin 2021 08h00 HE
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, June 23, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...